Search Results - "Forst T"

Role of C-Peptide in the Regulation of Microvascular Blood Flow.

Authors: Forst, T. Kunt, T. Wilhelm, B. et al.

Source: Experimental Diabetes Research. 2009, Special section p1-8. 8p. 3 Diagrams, 4 Graphs.

Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.

Authors: Grunberger, G. Forst, T. Fernández Landó, L. et al.

Source: Diabetic Medicine. Mar2016, Vol. 33 Issue 3, p391-394. 4p.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Authors: Forst, T. Guthrie, R. Goldenberg, R. et al.

Source: Diabetes, Obesity & Metabolism. May2014, Vol. 16 Issue 5, p467-477. 11p.

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Authors: Kapitza, C. Forst, T. Coester, H.‐V. et al.

Source: Diabetes, Obesity & Metabolism. Jul2013, Vol. 15 Issue 7, p642-649. 8p. 3 Charts, 1 Graph.

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.

Authors: Forst, T. Dworak, M. Berndt‐Zipfel, C. et al.

Source: Diabetes, Obesity & Metabolism. Jun2013, Vol. 15 Issue 6, p576-579. 4p. 1 Chart, 1 Graph.

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.

Authors: Forst, T. Michelson, G. Ratter, F. et al.

Source: Diabetic Medicine. Sep2012, Vol. 29 Issue 9, p1115-1118. 4p. 1 Chart, 1 Graph.

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.

Authors: Forst, T. Uhlig-Laske, B. Ring, A. et al.

Source: Diabetes, Obesity & Metabolism. Jun2011, Vol. 13 Issue 6, p542-550. 9p. 1 Diagram, 4 Charts, 1 Graph.

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes T. Forst et al. Linagliptin added to metformin in Type 2 diabetes.

Authors: Forst, T. Uhlig-Laske, B. Ring, A. et al.

Source: Diabetic Medicine. Dec2010, Vol. 27 Issue 12, p1409-1419. 11p. 1 Diagram, 4 Charts, 3 Graphs.

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes.

Authors: Forst, T. Larbig, M. Hohberg, C. et al.

Source: Diabetes, Obesity & Metabolism. May2010, Vol. 12 Issue 5, p437-441. 5p. 2 Charts, 1 Graph.

Time-Action Profile and Patient Assessment of Inhaled Insulin via the Exubera Device in Comparison with Subcutaneously Injected Insulin Aspart via the FlexPen Device.

Authors: Forst T Hohberg C Schöndorf T et al.

Source: Diabetes Technology & Therapeutics. Feb2009, Vol. 11 Issue 2, p87-92. 6p.

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Authors: Forst, T. Karagiannis, E. Lübben, G. et al.

Source: Atherosclerosis (00219150). Mar2008, Vol. 197 Issue 1, p311-317. 7p.

Anti-inflammatory effects of pioglitazone and/or simvastatin in patients with distinct clinical risk for cardiovascular complications.

Authors: Hanefeld M Forst T

Source: Cardiology Review. Jul2007, Vol. 24 Issue 7, p12-16. 5p.

Performance of the continuous glucose monitoring system (CGMS) during development of ketosis in patients on insulin pump therapy.

Authors: Pfützner, J. Forst, T. Butzer, R. et al.

Source: Diabetic Medicine. Oct2006, Vol. 23 Issue 10, p1124-1129. 6p.

IRIS II study: the IRIS II score -- assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes.

Authors: Forst T Standl E Hohberg C et al.

Source: Diabetic Medicine. Oct2004, Vol. 21 Issue 10, p1149-1153. 5p.

URL: 14509347

Effects of C-peptide on Microvascular Blood Flow and Blood Hemorheology.

Authors: Forst, T. Kunt, T.

Source: Experimental Diabesity Research. Jan-Mar2004, Vol. 5 Issue 1, p51-64. 14p.

The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus.

Authors: Pfützner, A. Forst, T. Engelbach, M. et al.

Source: Diabetic Medicine. Jun2001, Vol. 18 Issue 6, p489-494. 6p. 2 Charts, 2 Graphs.

Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDOM Complications Study.

Authors: Idzior-Walus, B. Mattock, M.B. Solnica, B. et al.

Source: Diabetic Medicine. 2001: Vol. 18 Issue 10. p. 786-796-796.

TREATMENT OF COTTON FABRICS TYPE WITH MOLDOTAN POLYURETHANE.

Authors: Forst T. Butnaru R. Muresan R. et al.

Source: Cellulose Chemistry & Technology. Jan/Feb1985, Vol. 19 Issue 1, p51. 1p.

MODIFICATION OF THE DYEABILITY OF WOOL BY CHEMICAL TREATMENTS. PART 1.

Authors: Forst T. Malcomete O. Muresan R. et al.

Source: Industria Usoara: Textile, Tricotaje, Confectii Textile. Feb1989, Vol. 40 Issue 2, p82. 1p.

DETERMINING THE COLORISTIC CLASS OF TEXTILE DYES.

Authors: Calin C. Forst T.

Source: Industria Usoara: Textile, Tricotaje, Confectii Textile. Jun1988, Vol. 39 Issue 6, p264. 1p.